| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514378000 | 1,2-oxazoles (including hydrogenated) | 83 |
| 20100035948 | Furanone compounds and lactam analogues thereof - The present invention provides a compound of formula I and a compound of formula II, methods of use and formulations thereof. | 02-11-2010 |
| 20100160398 | Farnesoid X Receptor Agonists - The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same. | 06-24-2010 |
| 20090042957 | Substituted Oxyarenes - The invention relates to compounds of the formula (I) | 02-12-2009 |
| 20130046001 | PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION - Provided is a pharmaceutical composition for inhibiting apoptosis of neurons or neurodegeneration. The pharmaceutical composition effectively prevents or treats diseases related to apoptosis of neurons or neurodegeneration. | 02-21-2013 |
| 20090306158 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 - Compounds in accord with Formula I: | 12-10-2009 |
| 20130123314 | METHOD FOR IMPROVING CARTILAGE REPAIR AND/OR PREVENTING CARTILAGE DEGENERATION IN A JOINT - The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and/or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is preferably selected from the group consisting of agents that stimulate chondrogenic differentiation and/or cartilage matrix synthesis; agents that inhibit osteogenesis and/or hypertrophy, anti-inflammatory agents, agents that inhibit apoptosis of chondrocytes, agents that inhibit senescence of chondrocytes and agents that enhance lubrication of a joint. | 05-16-2013 |
| 20100273844 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING MIGAINES - The present invention provides a method for treating or preventing one or more types of migraines by administering a monoamine oxidase inhibitor, preferably isocarboxazid, in a rapid-release formulation. The present invention also provides a pharmaceutical composition suitable for treating or preventing migraines and having at least one monoamine oxidase inhibitor. | 10-28-2010 |
| 20090099244 | ORGANIC COMPOUNDS - The invention relates to compound of the formula I | 04-16-2009 |
| 20090143451 | COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME - Compounds, and methods of using the same, are provided which increase the expression of telomerase reverse transcriptase (TERT) in a cell. These compounds and methods find use in a variety of applications in which increased expression of telomerase is desired, including immortalization of cell lines and treating conditions in a subject characterized by cellular senescence. | 06-04-2009 |
| 20090062356 | SUBSTITUTED BENZIMIDAZOLE DERIVATIVES - The invention is concerned with novel substituted benzimidazole derivatives of formula (I) | 03-05-2009 |
| 20090042958 | Composition and method for treating immune-mediated skin disorders - Liquid or semi-liquid pharmaceutical compositions for topically treating immune-mediated skin disorders such as psoriasis, eczema, acne, dermatitis, and skin cancer and methods of treating patients having such immune-mediated skin disorders using the compositions. | 02-12-2009 |
| 20090170916 | Pyrrole and Pyrazole DAAO Inhibitors - Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: | 07-02-2009 |
| 20080262057 | Diarylisoxazolines - The invention disclosed in this document is related to field of pesticides and their use in controlling pests. | 10-23-2008 |
| 20090186927 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHODS OF MAKING THE SAME - The present invention provides new trans-9,10-dehydroepothilone C and trans-9,10-dehydroepothilone D based derivative compounds, compositions and methods of inhibiting cellular hyperproliferation and/or stabilizing microtubules in vitro and of treatment of hyperproliferative diseases in vivo. Also disclosed are methods of making the compounds. | 07-23-2009 |
| 20090042959 | COMPOUNDS HAVING IMMUNOMODULATOR ACTIVITY - Compounds of formula I | 02-12-2009 |
| 20090137647 | Modified Macrophage Migration Inhibitory Factor Inhibitors - Provided are various compounds of Formula I (I). Also provided are various compounds of Formula II (II). Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also providcd are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor. | 05-28-2009 |
| 20090048315 | Method of alleviating chronic pain via peripheral glutaminase regulation - A composition having sustained pain-relieving properties such that the composition may be administered to a subject to alleviate chronic pain. The composition includes an effective amount of at least one glutaminase inhibitor. A method for alleviating chronic pain in a subject for an extended period of time is also disclosed, in which the compound is administered to a subject suffering from chronic pain at a site of inflammation such that the administration of the compound results in a reduction in at least one of thermal and mechanical pain responses at the site of inflammation for a period of at least two days without any resulting acute pain behavior. The composition may further include an effective amount of at least one compound having analgesic effects such that the composition also alleviates acute pain. | 02-19-2009 |
| 20090298898 | PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES - Compounds of formula | 12-03-2009 |
| 20100261772 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators - The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation. | 10-14-2010 |
| 20100267784 | NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY - This invention relates to novel 4,5-dihydroisoxazoles of formula (I), to their use as estrogen receptor modulators, and to methods of their preparation. | 10-21-2010 |
| 20090163562 | ORAL COMPOSITION COMPRISING 3-[5-[4-(CYCLOPENTYLOXY) -2-HYDROXYBENZOYL]-2-[(3-HYDROXY-1,2-BENZISOXAZOL-6- YL)METHOXY]PHENYL]PROPIONIC ACID OR SALT THEREOF - An oral composition contains 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl}propionic acid or a salt thereof and polyvinylpyrrolidone is advantageous as an oral medication composition (1) which can be produced without requiring new manufacturing equipment; (2) which can be produced with simple steps; (3) which maintains stable solubility even with changes in the pH of the gastrointestinal tract and of which gastrointestinal tract absorption is improved. | 06-25-2009 |
| 20090318516 | SOLID FORMS OF (1R,2S,3R)-1-(2-(ISOXAZOL-3-YL)-1H-IMIDAZOL-4-YL)BUTANE-1,2,3,4-TETRAOL AND METHODS OF THEIR USE - Solid forms of (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol and hydrates thereof are disclosed, as well as compositions comprising them and methods of their use. | 12-24-2009 |
| 20090076103 | STEM CELL DIFFERENTIATING AGENTS AND USES THEREFOR - The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively. | 03-19-2009 |
| 20110130432 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors - This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production. Formula (I) | 06-02-2011 |
| 20110251247 | SUBSTITUTED ISOXAZOLINE DERIVATIVES - This invention recites substituted isoxazoline derivatives of Formula (1) | 10-13-2011 |
| 20100240722 | FLUORINE-CONTAINING ORGANOSULFUR COMPOUND AND PESTICIDAL COMPOSITION COMPRISING THE SAME - There is provided a fluorine-containing organosulfur compound having an excellent controlling effect m represents 0 or 1; n represents 0, 1 or 2; A represents an optionally substituted 5-membered aromatic heterocyclic group; R | 09-23-2010 |
| 20100305176 | (S,R.)-3-PHENYL-4,5 DIHYDRO-5-ISOXAZOLE ACETIC ACID-NITRIC OXIDE AND USE THEREOF AS ANTI-CANCER AND ANTIVIRAL AGENT - The present invention relates to an isoxazole derivative, the compound of formula (I) | 12-02-2010 |
| 20100144808 | SUBSTITUTED ISOXAZOLINE OR ENONE OXIME COMPOUND, AND PEST CONTROL AGENT - Disclosed is a novel pest control agent, in particular a pesticide or a miticide. Specifically disclosed are a substituted isoxazoline compound or a substituted enone oxime compound represented by the general formula (1) below or the general formula (2) below, and a pest control agent containing any of them. (In the formulae, the symbols are as defined in the description.) | 06-10-2010 |
| 20080214636 | Glycyrrhetinic Acid-30-Amide Derivatives and Their Use - The present invention relates to the field of a medicine for treating diseases associated with inflammation, immunity or infection, and in particular, to glycyrrhetinic acid-30-amide derivatives of general formula I and their preparation, and a pharmaceutical composition containing the same. Said derivatives and composition exhibit anti-inflammatory, analgesic, anti-allergic, cough-preventing, liver-protecting and anti-viral properties, | 09-04-2008 |
| 20110166193 | INSECTICIDAL COMPOUNDS - A compound of Formula (I): where A | 07-07-2011 |
| 20110201661 | Spiro Derivatives of Parthenin as Novel Anticancer Agents - The present invention relates to novel spiro derivatives of parthenin prepared by the dipolar cycloaddition of various dipoles viz, benzonitrile oxides, nitrones, azides, nitrile ylide diazoalkane, nitrile imide, ozone, azomethine imides, azomethine ylides etc. with exocyclic double bond of C ring (α-methylene-γ-butyrolactone). Representative compounds have been screened for their anticancer activity against different cancer cell lines. ICs0 value of these analogues varies between 4.3 μM to 93 μM. A mechanistic correlation of their anticancer activity has been described. The results of the cytotoxicity test of the compounds studies indicated that the α,β-unsaturated ketonic moiety in parthenin plays an important role in the maintenance of the high level of cytotoxicity. | 08-18-2011 |
| 20100022608 | Non-steroidal anti-inflammatory drugs for cough - The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs. | 01-28-2010 |
| 20100016391 | Isoxazoline Compounds Having MIF Antagonist Activity - Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis). | 01-21-2010 |
| 20090197928 | Novel Receptor Antagonists and Their Methods of Use - The present invention relates to novel isoxazole derivatives of formula (I) which bind to the P2X7 receptor and are capable of interfering with the effects of ATP at the P2X7 receptor: | 08-06-2009 |
| 20120046325 | Isoxazoline Compounds Having MIF Antagonist Activity - Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis). | 02-23-2012 |
| 20120029040 | ANIMAL ECTOPARASITE-CONTROLLING AGENT - The present invention provides an animal ectoparasite-controlling agent containing as an active ingredient a hydrazide compound represented by the formula (1) | 02-02-2012 |
| 20120029038 | ANIMAL ECTOPARASITE-CONTROLLING AGENT - The present invention provides an animal ectoparasite-controlling agent containing as an active ingredient a hydrazide compound represented by the formula (1) | 02-02-2012 |
| 20120029037 | ANIMAL ECTOPARASITE-CONTROLLING AGENT - The present invention provides an animal ectoparasite-controlling agent containing as an active ingredient a hydrazide compound represented by the formula (1) | 02-02-2012 |
| 20120029039 | ANIMAL ECTOPARASITE-CONTROLLING AGENT - The present invention provides an animal ectoparasite-controlling agent containing as an active ingredient a hydrazide compound represented by the formula (1) | 02-02-2012 |
| 20110065764 | 5- PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS - The present invention relates to isoxazole-3-carboxamide derivative having the general Formula (I), or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-3-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, respiratory diseases, and lower urinary tract disorders. | 03-17-2011 |
| 20100048652 | INSECTICIDAL COMPOUNDS - A compound of formula (I): wherein A | 02-25-2010 |
| 20120322840 | Transdermally Absorbable Preparation Containing Basic Anti-Inflammatory Analgesic - A transdermally absorbable preparation in which a basic anti-inflammatory analgesic is formulated is provided to be an external adhesive patch, which has excellent drug releasing without damaging the physical properties of a plaster. The preparation can achieve high releasing of the basic anti-inflammatory analgesic without losing the releasing of the local anesthetic. Specifically provided is a transdermally absorbable adhesive patch, which contains both the basic anti-inflammatory analgesic and the local anesthetic as the absorption promoter for the basic anti-inflammatory analgesic. The basic anti-inflammatory analgesic has the acid dissociation constant (pKa) of 7 or more. The content of the basic anti-inflammatory analgesic is from 0.1% to 10% by weight to the total weight of the drug-containing plaster, and the content of the absorption promoter is from 0.01% to 20% by weight to the total weight of the drug-containing plaster in the transdermally absorbable adhesive patch. | 12-20-2012 |
| 20110237633 | SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY - The present invention provides compounds and pharmaceutically acceptable compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which hepatocyte growth factor/scatter factor (HGF/SF) or the activities thereof, or agonists or antagonists thereof, have a therapeutically useful role. | 09-29-2011 |
| 20110160259 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners - One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer. | 06-30-2011 |
| 514379000 | Polycyclo ring system having the oxazole ring as one of the cyclos | 13 |
| 20110112158 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS - Provided herein are compounds of the formula (I): | 05-12-2011 |
| 20090275628 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments - The present invention relates to substituted spiro compounds, to processes for preparing them, to medicaments comprising these compounds and to the use of these compounds for producing medicaments. | 11-05-2009 |
| 20090163563 | Phorboxazole Compounds and Methods of Their Preparation - Novel macrolactone compounds, their methods of preparation, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the macrolactone compounds may be useful, inter alia, for treating various cancers, inducing apoptosis in malignant cells, or inhibiting cancer cell division. | 06-25-2009 |
| 20080319036 | METHOD FOR TREATING OBESITY - The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism. | 12-25-2008 |
| 20110039901 | PROCESS FOR PREPARING A CRYSTALLINE FORM COMPOUND OF 3-BENZYL-2-METHYL-2,3,3a,4,5,6,7,7a-OCTAHYDROBENZO[d]ISOXAZOL-4-ONE - A process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one is described, comprising the step of reacting 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one and fumaric acid in one or more solvents, wherein at least one solvent is a solvent having a carbon atom number of from 3 to 6, said solvent being non-halogenated and having a dielectric constant ∈ in the range from 4 to 25. The process of the invention enables to obtain a co-crystal comprising 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one and fumaric acid. | 02-17-2011 |
| 20110130433 | Hepatitis C Virus Inhibitors - This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. | 06-02-2011 |
| 20100069451 | SALT OF 3-BENZYL-2-METHYL-2,3,3A,4,5,6,7, 7A- OCTAHYDROBENZO[D]ISOXAZOL-4-ONE - The present invention relates to oxalate salt of the compound of formula (I) in all its stereochemical configurations, a process for its preparation and its use in treating mood disorders, disorders of anxiety, depression and convulsive conditions, in the improvement of learning ability, in the reversal of amnesia, in resolving the abstinence syndrome from drugs and drugs of abuse. Preferably, the invention concerns oxalate salt of rel-(3R,3aS,7aS)-3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one. | 03-18-2010 |
| 20100069450 | SALT OF 3-BENZYL-2-METHYL-2,3,3A,4,5,6,7, 7A- OCTAHYDROBENZO[D]ISOXAZOL-4-ONE - The present invention relates to fumarate salt of the compound of formula (I) in all its stereochemical configurations, a process for its preparation and its use in treating mood disorders, disorders of anxiety, depression and convulsive conditions, in the improvement of learning ability, in the reversal of amnesia, in resolving the abstinence syndrome from drugs and drugs of abuse. Preferably, the invention concerns fumarate salt of rel-(3R,3aS,7aS)-3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one. | 03-18-2010 |
| 20110082180 | ANTIMICROBIAL COMPOUNDS - The compounds disclosed herein are isoxazole derivatives that are useful as antimicrobial compounds, particularly as anti-bacterial compounds. The disclosed methods comprise incubating at least two different substrates in the presence of at least one oxygenase to provide the disclosed compounds, or to prepare and identify compounds that have antimicrobial activity. | 04-07-2011 |
| 20080312301 | Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof - The invention relates to substituted N-benzo[d]isoxazol-3-yl-amine derivatives of formula (I) wherein R | 12-18-2008 |
| 20120046326 | DRUG CONTAINING BENZOPHENONE DERIVATIVE OR ITS SALT - Pharmaceutical agents characterized by containing benzophenone derivatives represented by the general formula: | 02-23-2012 |
| 20110039902 | PROCESS FOR PREPARING A CRYSTALLINE FORM COMPOUND OF 3-BENZYL-2-METHYL-2,3,3a,4,5,6,7,7a-OCTAHYDROBENZO[d]ISOXAZOL-4-ONE - A process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one is described, comprising the step of reacting 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydroben-zo[d]isoxazol-4-one with oxalic acid in one or more solvents, wherein at least one solvent is a solvent having a carbon atom number of from 3 to 6, said solvent being non-halogenated and having a dielectric constant ∈ within the range from 4 to 25. The process of the invention enables a co-crystal comprising 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one and oxalic acid to be obtained. | 02-17-2011 |
| 20100168192 | BENZISOXAZOLE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS FOR THE TREATMENT OF E.G. RESPIRATORY DISEASES, EPILEPSY AND CONVULSIONS - This invention relates to novel benzisoxazole derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels e.g. a respiratory disease, epilepsy or convulsions. X represents a substituent selected from the group consisting of CO—NR′R″, CO—O—R′, CO—NH—S, CO—NH—SO | 07-01-2010 |
| 514380000 | Chalcogen or nitrogen bonded directly to ring carbon of the oxazole ring | 26 |
| 20090215842 | Method of Treating Schizophrenia Prodrome - The present invention relates to a method of treating schizophrenia prodrome in human subjects using a NMDA glycine site agonist, a glycine transporter-1 inhibitor or mixtures thereof, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient. | 08-27-2009 |
| 20110196005 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 08-11-2011 |
| 20130041000 | NOVEL AZOLE COMPOUND - Azole compounds represented by formula I: | 02-14-2013 |
| 20090118341 | Method for treatment of chronic neuropathic pain - Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as D-cycloserine or a GlyT-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may also contain a secondary analgesic such as opiates, NSAIDs or cox-2 inhibitors. The analgesic can be formulated in a pharmaceutical composition in the form of an injectable solution that contains at least two different analgesics, at least one of the analgesics of which is a glycine receptor agonist or a GlyT-1 glycine transporter antagonist. Suitable pharmaceutical compositions contain D-cycloserine and/or sarcosine, optionally in combination with opiates, NSAIDs or cox-2 inhibitors. | 05-07-2009 |
| 20130096168 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors - The present invention provides a compound of formula I; | 04-18-2013 |
| 20120225916 | Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine - The invention describes methods and compositions for alleviating medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical compound that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction, wherein D-cycloserine is the pharmaceutical compound that enhances learning. Representative afflictions include pain, mood disorders, anxiety disorders including performance anxiety, insomnia, female sexual dysfunction, chronic fatigue, autism spectrum disorders, fibromyalgia, and attention deficit-hyperactivity disorder. | 09-06-2012 |
| 20110301211 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 12-08-2011 |
| 20100056589 | PLANT DISEASE DAMAGE CONTROL COMPOSITION AND PLANT DISEASE DAMAGE PREVENTION AND CONTROL METHOD - The invention provides a plant disease control composition including active ingredients of (RS)—N-[2-(1,3-dimethylbutyl)thiophene-3-yl]-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide (common name: penthiopyrad) and at least one fungicidal compound other than penthiopyrad, and a plant disease prevention method wherein such a compound is applied to plant seeds or soil. According to the invention, a composition and a prevention method are provided which demonstrate a prevention effect against plural types of disease pathogenic microbes, and also demonstrate a preventing effect to currently emerging resistant pathogenic microbes, when applied to plant seed or soil. | 03-04-2010 |
| 20100298393 | Modulation of Growth Hormone, DHEA, and Cortisol with Positive Modulators of AMPA Type Glutamate Receptors - Methods for modulating the endocrine system of a mammal are provided. In the subject methods, a positive allosteric modulator of AMPA receptors of the hypothalamus are administered to the host. The subject methods find use in applications where it is desired to increase the baseline circulatory level of a growth hormone in a mammalian host. The subject methods also find use in applications where it is desired to increase the circulatory level of DHEA in a mammalian host. Finally, another subject method also finds use in applications where it is desired to decrease the circulatory level of cortisol in a mammalian host. | 11-25-2010 |
| 20100280086 | SUBSTITUTED THIOPHENES - Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 11-04-2010 |
| 20080269304 | Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use - It is intended to provide a substance having an effect of shrinking pores by analyzing the mechanism of making pores perceptible and compositions such as a skin preparation for external use which exerts the above effect to thereby make pores imperceptible. As means for solving these problems, there are provided a parakeratosis inhibitor and a pore-shrinking agent comprising an antagonist to an excitatory cell receptor, for example, a glutamate receptor such as N-methyl-D-aspartic acid receptor or an ATP receptor such as P2X receptor, or an agonist to an inhibitory cell receptor such as a γ-aminobutyrate receptor such as bicuculline-sensitive receptor having the Cl-channel therein or glycine receptor, as well as a skin preparation for external use aiming at inhibiting parakeratosis and a skin preparation for external use aiming at shrinking pores each containing such an antagonist to an excitatory cell receptor or an agonist to an inhibitory cell receptor as described above. Owing to the effects of inhibiting parakeratosis and shrinking pores, the skin can be maintained in a healthy state without perceptible pores. | 10-30-2008 |
| 20110207788 | 5-Ring Heteroaromatic compounds and their use as binding partners for 5-ht5 receptors - The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for the treatment and/or prevention of diseases, and medicaments containing same. | 08-25-2011 |
| 20100152257 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 06-17-2010 |
| 20100173962 | HETEROARYL (SUBSTITUTED)ALKYL N-SUBSTITUTED SULFOXIMINES AS INSECTICIDES - N-Substituted heteroaryl (substituted)alkyl sulfoximines are effective at controlling insects. | 07-08-2010 |
| 20110124695 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors - The present invention provides a compound of formula I: | 05-26-2011 |
| 20110124696 | Sulfone Compounds Which Modulate The CB2 Receptor - Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 05-26-2011 |
| 20110082181 | Compounds as Lysophosphatidic Acid Receptor Antagonists - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 04-07-2011 |
| 20110160260 | Method of Treating a Neurodegenerative Disorder - The present invention provides a method of treating a neurodegenerative disorder in a patient, comprising administration to the patient a therapeutically effective amount of D-cycloserine and its derivatives. | 06-30-2011 |
| 20120202862 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors - The present invention provides a compound of formula I; | 08-09-2012 |
| 20110021584 | Methods and Assays for Detecting and Treating Hypoglycemia - Methods for regulating glucagon release and of treating hypoglycemia, and for screening drug candidates for treating hypoglycemia. The methods are useful for treating diabetes mellitus and screening drug candidates for potential efficacy. | 01-27-2011 |
| 20100298392 | Isoindoline Derivatives For The Treatment Of Arrhythmias - There is provided compounds of formula I, wherein R | 11-25-2010 |
| 20100048653 | NEUROPROTECTIVE MODULATION OF NMDA RECEPTOR SUBTYPE ACTIVITIES - In various aspects, the invention provides methods and compositions for modulating NMDA receptor subtype activity, to enhance NR2A-containing NMDA receptor activity relative to NR2B-containing NMDA receptor activity, so as to effect a neuroprotective reduction in excitotoxic NMDA receptor activity | 02-25-2010 |
| 20110039903 | Acute Pharmacologic Augmentation of Psychotherapy with Enhancers of Learning or Conditioning - Methods for treating an individual with a psychiatric disorder with a pharmacologic agent that enhances learning or conditioning in combination with a session of psychotherapy are provided. These methods of the invention encompass a variety of methods of psychotherapy, including exposure-based psychotherapy, cognitive psychotherapy, and psychodynamically oriented psychotherapy, and psychiatric disorders including fear and anxiety disorders, addictive disorders including substance-abuse disorders, and mood disorders. The pharmacologic agents used for the methods of the present invention are ones that generally enhance learning or conditioning, including those that increase the level of acetylcholine in the brain, and those that enhance N-methyl-D-aspartate (NMDA) receptor transmission in the brain. | 02-17-2011 |
| 20090131491 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I - Disclosed is a compound useful as an inhibitor of 11β-hydroxysteroid dehydrogenase type 1. | 05-21-2009 |
| 20100204291 | Method for Facilitating Extinction Training Using D-Cycloserine - Methods are disclosed for improving treatment of various medical conditions via administration of D-cycloserine to facilitate learning. Specifically, by administering D-cycloserine on a post-training pre-sleep basis, subsequent to extinction training during the day, the methods can improve upon the known ability of D-cycloserine to facilitate extinction learning. | 08-12-2010 |
| 20100204290 | PROCEDURE FOR OPERATING A PARTICLE FILTER ARRANGED IN AN EXHAUST FUME AREA OF A BRENNKRAFTMASCHINE AND DEVICE TO EXECUTE THE PROCEDURE - A method of increasing the survival of animals and aquatic species susceptible to birnavirus infection by treating them before, during and/or after bimavirus exposure, with a chemical compound capable of inhibiting viral replication. A method of treating aquatic species to increase their survival in the presence of a virus, particularly an aquatic bimavirus, and to increase the yield of farmed fish susceptible to viral infection. The present invention provides methods for increasing survival of virally-exposed aquatic animals by administering therapeutically effective amounts of isoxazol compounds to aquatic animals susceptible to bimavirus infection and/or IPNV infection, particularly in fish such as salmonoid species, which are easily exposed to IPNV. The present invention also provides methods for increasing survival of virally-exposed animals by administering therapeutically effective amounts of isoxazol compounds to farmed animals susceptible to bimavirus infection and/or IBDV infection, particularly in poultry such as chickens, which are exposed to IBDV. | 08-12-2010 |
